source
- Novartis scraps TREM2 ALS candidate after Phase 2 failureNovartis announced it is halting development of its TREM2-targeting drug VHB937, also known as lifonebart, after the Phase 2 trial in amyotrophic lateral sclerosis (ALS) did not meet its primary en…
- Sling Therapeutics raises $123M to fund Phase 3 trial of former Astellas cancer drug for thyroid eye diseaseInvestors have committed $123 million to Sling Therapeutics, a small Michigan biotech focused on eye‑disease treatments. The funding will support a Phase 3 clinical trial of a drug originally deve…